Literature DB >> 12368681

Long-term results of local excision for rectal cancer.

Philip B Paty1, Garrett M Nash, Paul Baron, Maureen Zakowski, Bruce D Minsky, David Blumberg, Daniel R Nathanson, Jose G Guillem, Warren E Enker, Alfred M Cohen, W Douglas Wong.   

Abstract

OBJECTIVE: To review the authors' experience with local excision of early rectal cancers to assess the effectiveness of initial treatment and of salvage surgery. SUMMARY BACKGROUND DATA: Local excision for rectal cancer is appealing for its low morbidity and excellent functional results. However, its use is limited by inability to assess regional lymph nodes and uncertainty of oncologic outcome.
METHODS: Patients with T1 and T2 adenocarcinomas of the rectum treated by local excision as definitive surgery between 1969 to 1996 at the authors' institution were reviewed. Pathology slides were reviewed. Among 125 assessable patients, 74 were T1 and 51 were T2. Thirty-one patients (25%) were selected to receive adjuvant radiation therapy. Fifteen of these 31 patients received adjuvant radiation in combination with 5-fluorouracil chemotherapy. Median follow-up was 6.7 years. One hundred fifteen patients (92%) were followed until death or for greater than 5 years, and 69 patients (55%) were followed until death or for greater than 10 years. Recurrence was recorded as local, distant, and overall. Survival was disease-specific.
RESULTS: Ten-year local recurrence and survival rates were 17% and 74% for T1 rectal cancers and 26% and 72% for T2 cancers. Median time to relapse was 1.4 years (range 0.4-7.0) for local recurrence and 2.5 years (0.8-7.5) for distant recurrence. In patients receiving radiotherapy, local recurrence was delayed (median 2.1 years vs. 1.1 years), but overall rates of local and overall recurrence and survival rates were similar to patients not receiving radiotherapy. Among 26 cancer deaths, 8 (28%) occurred more than 5 years after local excision. On multivariate analysis, no clinical or pathologic features were predictive of local recurrence. Intratumoral vascular invasion was the only significant predictor of survival. Among 34 patients who developed tumor recurrence, the pattern of first clinical recurrence was predominantly local: 50% local only, 18% local and distant, and 32% distant only. Among the 17 patients with isolated local recurrence, 14 underwent salvage resection. Actuarial survival among these surgically salvaged patients was 30% at 6 years after salvage. CONCLUSIONS The long-term risk of recurrence after local excision of T1 and T2 rectal cancers is substantial. Two thirds of patients with tumor recurrence have local failure, implicating inadequate resection in treatment failure. In this study, neither adjuvant radiotherapy nor salvage surgery was reliable in preventing or controlling local recurrence. The postoperative interval to cancer death is as long as 10 years, raising concern that cancer mortality may be higher than is generally appreciated. Additional treatment strategies are needed to improve the outcome of local excision.

Entities:  

Mesh:

Year:  2002        PMID: 12368681      PMCID: PMC1422607          DOI: 10.1097/00000658-200210000-00015

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  29 in total

1.  Variables correlated with the risk of lymph node metastasis in early rectal cancer.

Authors:  J T Brodsky; G K Richard; A M Cohen; B D Minsky
Journal:  Cancer       Date:  1992-01-15       Impact factor: 6.860

2.  Conservative treatment of distal rectal cancer by local excision.

Authors:  J J DeCosse; R J Wong; S H Quan; N B Friedman; S S Sternberg
Journal:  Cancer       Date:  1989-01-15       Impact factor: 6.860

3.  Is local excision adequate therapy for early rectal cancer?

Authors:  A Mellgren; P Sirivongs; D A Rothenberger; R D Madoff; J García-Aguilar
Journal:  Dis Colon Rectum       Date:  2000-08       Impact factor: 4.585

4.  Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy oncology group protocol 89-02.

Authors:  A H Russell; J Harris; P J Rosenberg; W T Sause; B J Fisher; J P Hoffman; W G Kraybill; R W Byhardt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

5.  Safety and efficacy of low anterior resection for rectal cancer: 681 consecutive cases from a specialty service.

Authors:  W E Enker; N Merchant; A M Cohen; N M Lanouette; C Swallow; J Guillem; P Paty; B Minsky; K Weyrauch; S H Quan
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

Review 6.  Risk of lymph node metastasis in T1 carcinoma of the colon and rectum.

Authors:  Riccardo Nascimbeni; Lawrence J Burgart; Santhat Nivatvongs; Dirk R Larson
Journal:  Dis Colon Rectum       Date:  2002-02       Impact factor: 4.585

7.  Local excision of rectal cancer: what is the evidence?

Authors:  S Sengupta; J J Tjandra
Journal:  Dis Colon Rectum       Date:  2001-09       Impact factor: 4.585

8.  Local excision of cancer of the rectum.

Authors:  T Hager; F P Gall; P Hermanek
Journal:  Dis Colon Rectum       Date:  1983-03       Impact factor: 4.585

9.  Policy of local excision for early cancer of the colorectum.

Authors:  B C Morson; H J Bussey; S Samoorian
Journal:  Gut       Date:  1977-12       Impact factor: 23.059

10.  Effective surgical adjuvant therapy for high-risk rectal carcinoma.

Authors:  J E Krook; C G Moertel; L L Gunderson; H S Wieand; R T Collins; R W Beart; T P Kubista; M A Poon; W C Meyers; J A Mailliard
Journal:  N Engl J Med       Date:  1991-03-14       Impact factor: 91.245

View more
  67 in total

Review 1.  Transanal Endoscopic Microsurgery.

Authors:  Theodore John Saclarides
Journal:  Clin Colon Rectal Surg       Date:  2015-09

2.  Surgery for colorectal cancer in a low-volume unit: assessment of key issues in the achievement of acceptable clinical results.

Authors:  Hannu Paimela; Outi Lindström; Timo Tomminen; Mauri Iivonen; Esa Könönen; Pekka Kuusanmäki
Journal:  Int J Gastrointest Cancer       Date:  2005

3.  Oncological outcomes of transanal local excision for high risk T(1) rectal cancers.

Authors:  Ze-Yu Wu; Gang Zhao; Zhe Chen; Jia-Lin Du; Jin Wan; Feng Lin; Lin Peng
Journal:  World J Gastrointest Oncol       Date:  2012-04-15

4.  Prognostic factors for 5-year survival after local excision of rectal cancer.

Authors:  Dong-Bing Zhao; Yong-Kai Wu; Yong-Fu Shao; Cheng-Feng Wang; Jian-Qiang Cai
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

5.  A giant rectal villous adenoma with a malicious intent.

Authors:  Maen Aboul Hosn; Nafisa Abdel-Hafiez; Reham Abdel-Wahab; Abir Al-Ahmadie; Ahmad Antar; Haifaa Dbouk; Hassan El Farran; Mahmoud El-Sawy Mohamed; Khaled Rida; Deborah Mukherji; Eileen M O'Reilly; Julio Garcia-Aguilar; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-09

6.  Clinicopathological features of anastomotic recurrence after an anterior resection for rectal cancer.

Authors:  Kenji Matsuda; Tsukasa Hotta; Katsunari Takifuji; Shozo Yokoyama; Yoshimasa Oku; Hiroki Yamaue
Journal:  Langenbecks Arch Surg       Date:  2009-06-10       Impact factor: 3.445

7.  The Role of Transanal Surgery in the Management of T1 Rectal Cancers.

Authors:  Imran Hassan; Paul E Wise; David A Margolin; James W Fleshman
Journal:  J Gastrointest Surg       Date:  2015-06-06       Impact factor: 3.452

8.  p27 expression in post-treatment rectal cancer: a potential novel approach for predicting residual nodal disease.

Authors:  Tobias Leibold; Vanessa W Hui; Jinru Shia; Jeannine A Ruby; Elyn R Riedel; José G Guillem
Journal:  Am J Surg       Date:  2014-04-13       Impact factor: 2.565

9.  Local management of rectal neoplasia.

Authors:  John Touzios; Kirk A Ludwig
Journal:  Clin Colon Rectal Surg       Date:  2008-11

10.  Outcomes of Local Excision plus Chemoradiotherapy in Patients with T1 Rectal Cancer.

Authors:  Toshiyuki Suzuki; Sotaro Sadahiro; Akira Tanaka; Kazutake Okada; Gota Saito; Hiroshi Miyakita; Takeshi Akiba; Hiroshi Yamamuro
Journal:  Oncology       Date:  2018-06-15       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.